Feedback

Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation

Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Zelba, Henning;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
McQueeney, Alex;
ORCID
0000-0002-0553-2693
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Rabsteyn, Armin;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Bartsch, Oliver;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Kyzirakos, Christina;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Kayser, Simone;
Affiliation
CeGaT GmbH, 72076 Tuebingen, Germany
Harter, Johannes;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Latzer, Pauline;
Affiliation
Cecava GmbH, 72076 Tuebingen, Germany
Hadaschik, Dirk;
ORCID
0000-0001-6021-5837
Affiliation
CeGaT GmbH, 72076 Tuebingen, Germany
Battke, Florian;
Affiliation
Department of Obstetrics and Gynaecology University of Tuebingen, 72074 Tuebingen, Germany
Hartkopf, Andreas D.;
Affiliation
Zentrum für Humangenetik Tübingen, 72076 Tuebingen, Germany
Biskup, Saskia

Breast cancer is a tumor entity that is one of the leading causes of mortality among women worldwide. Although numerous treatment options are available, current explorations of personalized vaccines have shown potential as promising new treatment options to prevent the recurrence of cancer. Here we present a small proof of concept study using a prophylactic peptide vaccination approach in four female breast cancer patients who achieved remission after standard treatment. The patients were initially analyzed for somatic tumor mutations and then treated with personalized neoantigen-derived peptide vaccines. These vaccines consisted of HLA class I and class II peptides and were administered intracutaneously followed by subcutaneous application of sargramostim and/or topical imiquimod as an immunological adjuvant. After an initial priming phase of four vaccinations within two weeks, patients received monthly boosting/maintenance vaccinations. Chemotherapy or checkpoint inhibition was not performed during vaccination. One patient received hormone therapy. The vaccines were well tolerated with no serious adverse events. All patients displayed vaccine-induced CD4+ and/or CD8+ T-cell responses against various neoantigens. Furthermore, all patients remained tumor-free and had persistent T-cell responses, even several months after the last vaccination, suggesting the potential of peptide vaccines as an immunosurveillance and long term prophylaxis option.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2022 by the authors.

Use and reproduction: